Treatment of Recurrent Bladder Cancer With Dendritic Cells

Phase 2CompletedNCT04184232

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus17 enrolled

Overview

Treatment of recurrent bladder cancer with dendritic cells

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bladder Cancer

Interventions

Dendritic cellsBIOLOGICAL

Autologous dendritic cells primed with muc-1/wt-1 peptides

Standard treatment according to the Clinical protocolsOTHER

Standard treatment of bladder cancer according to the Clinical protocols

Eligibility

Sex: MALEMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed diagnosis of pTa bladder cancer; * Patient who require repetitive transurethral resection; * Expression of muc-1/wt-1 by the tumor; * EGOC 0-3; Exclusion Criteria: * any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis B/C, tuberculosis, HIV

Locations (1)

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Minsk, Belarus

Outcomes

Primary Outcomes

Efficacy evaluation

1 year relapse free survival

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.